资讯

STAT4 天
Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout
During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines’ Ayvakit ...
Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade
Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...